Clinuvel Pharmaceuticals Limited (CUV.AX)

ASX - ASX Delayed Price. Currency in AUD

Add to watchlist

15.38

-0.32

(-2.04%)

At close: 04:10PM AEST

Loading interactive chart...

GlobeNewswire
Afamelanotide in fair-skinned Parkinson’s patients
Preclinical models show benefit of afamelanotide as MC1R therapy in Parkinson’s DiseaseMELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease (PD or Parkinson’s) in fair-skinned patients. The program objectives are to determine whether afamelanotide – through melanocortin-1 receptor (MC1R) activation – is able to lower α-synuclein (a toxin) in blood levels in PD patients,
Simply Wall St.
Institutions own 21% of Clinuvel Pharmaceuticals Limited (ASX:CUV) shares but retail investors control 59% of the company
Key Insights The considerable ownership by retail investors in Clinuvel Pharmaceuticals indicates that they...
Simply Wall St.
Is Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Clinuvel Pharmaceuticals' (ASX:CUV) stock is up by a considerable 8.7% over the past month. Since the market usually...